• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多伟托（Doravirine/拉米夫定/替诺福韦艾拉酚胺富马酸盐）在初治 HIV-1 及传播型非核苷类逆转录酶抑制剂耐药突变患者中的疗效和安全性。

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.

机构信息

Department of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada.

Whitman-Walker Institute, Washington, DC.

出版信息

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.

DOI:10.1097/QAI.0000000000002153
PMID:31425317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6830961/
Abstract

Supplemental Digital Content is Available in the Text.

摘要

补充数字内容可在文本中查看。

相似文献

1
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.多伟托（Doravirine/拉米夫定/替诺福韦艾拉酚胺富马酸盐）在初治 HIV-1 及传播型非核苷类逆转录酶抑制剂耐药突变患者中的疗效和安全性。
J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.
2
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.切换至多伟拉韦/拉米夫定/富马酸替诺福韦二吡呋酯（DOR/3TC/TDF）治疗 48 周维持 HIV-1 病毒学抑制：DRIVE-SHIFT 试验结果。
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.
3
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.多伟拉韦/拉米夫定/替诺福韦酯富马酸与依非韦伦/恩曲他滨/替诺福韦酯富马酸治疗人类免疫缺陷病毒 1 感染初治成人的非劣效性：DRIVE-AHEAD 试验的第 48 周结果。
Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.
4
No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.多瑞韦拉、拉米夫定和替诺福韦酯共同给药时无显著药物相互作用。
Antivir Ther. 2019;24(6):443-450. doi: 10.3851/IMP3324.
5
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.比较多拉韦林、拉米夫定和富马酸替诺福韦二吡呋酯的 HIV 抗逆转录病毒药物口服颗粒制剂的生物等效性。
AAPS PharmSciTech. 2020 Feb 13;21(3):91. doi: 10.1208/s12249-020-1630-6.
6
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.简要报告：每日口服伊拉司他韦联合多伟拉韦利仑在初治 HIV-1 感染成人中治疗 96 周的疗效和安全性，这些患者接受伊拉司他韦、多伟拉韦利仑和拉米夫定的初始治疗。
J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):68-72. doi: 10.1097/QAI.0000000000002879. Epub 2021 Dec 8.
7
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.初治抗逆转录病毒治疗患者中，替诺福韦酯富马酸盐、恩曲他滨和依非韦伦与固定剂量齐多夫定/拉米夫定和依非韦伦的比较：病毒学、免疫学和形态学变化——一项96周分析
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40. doi: 10.1097/01.qai.0000245886.51262.67.
8
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.初治抗逆转录病毒治疗患者中逆转录酶和蛋白酶常见的HIV-1传播耐药突变以及对含富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺方案的反应
J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.
9
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.研究快报：DRIVE-SHIFT 试验中，换用 DOR/3TC/TDF 维持治疗可在第 144 周保持 HIV-1 病毒学抑制。
J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):801-805. doi: 10.1097/QAI.0000000000002642.
10
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.多伟拉韦与利托那韦增强的达芦那韦在初治 HIV-1 成人患者中的比较（DRIVE-FORWARD）：一项随机、双盲、非劣效性、3 期临床试验的 96 周结果。
Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.

引用本文的文献

1
Baseline survey of doravirine resistance among pregnant women with HIV.感染艾滋病毒孕妇中多拉韦林耐药性的基线调查。
Rev Esp Quimioter. 2025 Mar 3;38(2):139-141. doi: 10.37201/req/107.2024. Epub 2025 Feb 6.
2
Two-Drug Combination Antiretroviral Therapy for HIV-1: Case Series and Literature Review.用于治疗HIV-1的两药联合抗逆转录病毒疗法：病例系列及文献综述
Hosp Pharm. 2024 Nov 5:00185787241293374. doi: 10.1177/00185787241293374.
3
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.K103N、V106M 和 Y188L 显著降低 HIV-1 基因型 C 对多替拉韦的表型敏感性。
Viruses. 2024 Sep 20;16(9):1493. doi: 10.3390/v16091493.
4
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.多伟拉韦治疗经传播耐药性 HIV-1 感染者的潜在作用。
AIDS Res Ther. 2023 Feb 7;20(1):8. doi: 10.1186/s12981-023-00503-5.
5
High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen.在基于非核苷类逆转录酶抑制剂（NNRTI）的单片复方制剂治疗出现病毒学失败的HIV-1感染患者中，多瑞韦耐药的高流行率。
Infect Drug Resist. 2022 Jul 20;15:3857-3869. doi: 10.2147/IDR.S361012. eCollection 2022.
6
Approved HIV reverse transcriptase inhibitors in the past decade.过去十年中获批的HIV逆转录酶抑制剂。
Acta Pharm Sin B. 2022 Apr;12(4):1567-1590. doi: 10.1016/j.apsb.2021.11.009. Epub 2021 Nov 16.
7
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.HIV-1 耐药相关突变对多替拉韦敏感性的影响：真实临床分离株分析。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0121621. doi: 10.1128/AAC.01216-21. Epub 2021 Sep 27.
8
A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.一项评估伊拉曲韦（MK-8591）与多拉韦林在无 HIV 成人中药物相互作用的 1 期研究。
Clin Drug Investig. 2021 Jul;41(7):629-638. doi: 10.1007/s40261-021-01046-1. Epub 2021 Jun 21.
9
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.多伟拉韦在非洲的 HIV 治疗方案中是否有作用？南非一项大型的耐药观察性研究。
J Int AIDS Soc. 2021 May;24(5):e25706. doi: 10.1002/jia2.25706.
10
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.在含有多种 NNRTI 耐药突变的 HIV-1 克隆中，体外对多伟拉嗪的交叉耐药性。
J Antimicrob Chemother. 2021 Jan 1;76(1):130-134. doi: 10.1093/jac/dkaa401.

本文引用的文献

1
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.切换至多伟拉韦/拉米夫定/富马酸替诺福韦二吡呋酯（DOR/3TC/TDF）治疗 48 周维持 HIV-1 病毒学抑制：DRIVE-SHIFT 试验结果。
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.
2
The global burden of HIV-1 drug resistance in the past 20 years.过去20年中全球HIV-1耐药性负担。
PeerJ. 2018 May 25;6:e4848. doi: 10.7717/peerj.4848. eCollection 2018.
3
Doravirine: a review.多伟拉韦：综述。
Curr Opin HIV AIDS. 2018 Jul;13(4):308-314. doi: 10.1097/COH.0000000000000471.
4
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.在低收入和中等收入国家，开始或重新开始一线抗逆转录病毒治疗之前的 HIV-1 耐药性：系统评价和荟萃回归分析。
Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5.
5
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.利匹韦林和多拉韦林对非核苷类逆转录酶抑制剂耐药的HIV-1突变体具有互补疗效。
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):485-91. doi: 10.1097/QAI.0000000000001031.
6
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.多拉韦林在临床相关浓度下可抑制常见的非核苷类逆转录酶抑制剂相关突变体。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr.
7
Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.1999 - 2011年HIV门诊研究中未接受过抗逆转录病毒治疗者的基因型耐药性检测使用趋势及主要耐药频率
J Antimicrob Chemother. 2015 Aug;70(8):2337-46. doi: 10.1093/jac/dkv120. Epub 2015 May 15.
8
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.新型HIV非核苷类逆转录酶抑制剂多拉韦林在健康受试者单次及多次给药后的安全性、耐受性和药代动力学
Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3.
9
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.使用多拉韦林（MK-1439）进行体外耐药性筛选，多拉韦林是一种具有独特突变发展途径的新型非核苷类逆转录酶抑制剂。
Antimicrob Agents Chemother. 2015 Jan;59(1):590-8. doi: 10.1128/AAC.04201-14. Epub 2014 Nov 10.
10
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.欧洲新诊断的 HIV-1 感染者中对非核苷类逆转录酶抑制剂的传播耐药性增加。
BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.